| 0800 – 0900 |
Breakfast Satellite Symposium 2 |
| 0900 – 1015 |
Lymphoma Session
|
| 0900 – 0920 |
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin’s lymphoma
|
| 0920 – 0940 |
R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study
|
| 0940 – 1000 |
RIdiotype vaccine therapy (BiovaxIDTM) in follicular lymphoma in first complete remission: Phase III clinical trial results
|
| 1000 – 1015 |
Q&A Session
|
| 1015 – 1100 |
Tea Time Satellite Symposium 3 |
| 1100 – 1130 |
Exhibition & Networking
|
| 1130 – 1245 |
Genitourinary Session
|
| 1130 – 1150 |
A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC)
|
| 1150 – 1210 |
Phase III trial of toremifene citrate for the prevention of prostate cancer in men with high grade prostatic epithelial neoplasia
|
| 1210 – 1230 |
A randomized, double-blind phase III study of Pazopanib in treatment-naïve and cytokine-pretreated patients with advance renal cell carcinoma (RCC)
|
| 1230 – 1245 |
Q&A Session
|
| 1250 – 1400 |
Lunch Satellite Symposium 2
|
| 1400 – 1535 |
Lung Cancer Session
|
| 1400 – 1420 |
Molecular and Clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study
|
| 1420 – 1440 |
SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
|
| 1440 – 1500 |
A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
|
| 1500 – 1520 |
Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
|
| 1520 – 1535 |
Q&A Session
|
| 1535 – 1620 |
Tea Time Satellite Educational Session 4
|
| 1620 – 1650 |
Exhibition & Networking
|
| 1650 – 1805 |
Gastrointestinal Cancer Session II |
| 1650 – 1710 |
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: Results of the EORTC 22952-26001 study
|
| 1710 – 1730 |
A randomized, double-blind, placebo-controlled, multicenter phase 3 trial of everolimus + octreotide in patients with A phase III trial comparing mFolfox6 to mFolfox6 + bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08
|
| 1730 – 1750 |
Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954.
|
| 1750 – 1805 |
Q&A Session
|
| 1805 – 1815 |
Closing Address
|
| Program is correct at time of release and is subjected to changes. 11 June 2009 |
| |
| |
| • Download for the scientific programme guide click here |
